SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...
(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) and privately-held clinical-stage biotechnology company Capstan Therapeutics, Inc., announced Monday a definitive agreement under which AbbVie ...
(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A University of Pennsylvania ...
SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, today announced the ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up ...
A San Diego biotech is working on therapies that could tackle life-altering conditions, like autoimmune diseases and cancer, by modifying cells. But instead of engineering cells in a lab, they’re ...
Arcturus Therapeutics sued AbbVie and Capstan Therapeutics for allegedly misusing its lipid nanoparticle (LNP) delivery technology after former staff joined Capstan. The case spotlights the high ...
Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results